Navigation Links
Depression overlooked in patients with hepatitis C; compromising HCV therapy
Date:7/20/2010

Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, and that treatment-induced depression compromises the outcome of HCV therapy. A second U.S. study found that patients with chronic infection had lower (work) productivity and incurred higher medical benefit costs than those without HCV. Both studies are available in the August issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

HCV is a blood-born infection causing inflammation and destruction of liver cells. When inflammation lasts longer than six months there is ongoing liver cell injury which is defined as chronic HCV. The standard treatment protocol for chronic HCV is weekly injections of peg-interferon alfa-2a in combination with daily oral ribavirin for 24 to 48 weeks. However, this combination treatment can lead to major depression or other psychiatric complications in a number of HCV patients which may require premature termination of the antiviral therapy.

Peter Leutscher, M.D., Ph.D., and colleagues estimated the value of routine medical interviews in diagnosing depression in chronic HCV patients receiving peg-interferon/ribavirin therapy using the Major Depression Inventory (MDI). The MDI is a self-rating depression scale with a dual functionality in diagnosing major depression and in measurement of depression severity. Of the 325 HCV patients enrolled in the study, 6% were observed with major depression at baseline. Among the remaining 306 patients, 37% (n=114) developed depression while on HCV combination therapy. "According to the MDI criteria, we found that only 32% of the 114 patients with major depression were correctly diagnosed during routine medical interviews," noted Dr. Leutscher.

Researchers also noted that the emergence of major depression frequently led to premature discontinuation of the peg-interferon/ribavirin therapy. Those patients with higher MDI scores (30 and over) were more likely to have a diminished treatment outcome. "A self-report instrument such as the MDI scale may be a useful tool for health providers to identify patients at risk for depression during HCV therapy," recommended Dr. Leutscher.

Another HCV study published this month in Hepatology compared healthcare benefit costs and productivity issues for patients with and without chronic HCV infection. A total of 339,456 U.S. subjects were evaluated1664 employees with HCV and 337,792 in the healthy control. Rich Brook, lead study author said, "We found that employees with HCV infection experience significant health-related work absences, greater health benefit costs, and further comorbidity than those without infection."

Research results found HCV infected workers had 4.15 more total annual absence days and processed 7.5% fewer units of work per hour than those in the control group. Healthcare benefit costs were also significantly higher in the HCV group with a total incremental difference of $8,352 per year, including $490 in indirect (absence) costs.

Prior studies estimate that 180 million people are affected by HCV worldwide, and currently a vaccine to treat this disease is not available. Experts project that HCV will lead to a substantial health and economic burden over the next 10 to 20 years. "Our research supports this finding and provides a real world evaluation of HCV's impact on productivity and healthcare benefit costs in the workplace," concluded Mr. Brook.


'/>"/>
Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Husbands hostile, anti-social behaviors increase wives symptoms of depression, researchers find
3. Acupuncture May Ease Depression During Pregnancy
4. Belief in a caring god improves response to medical treatment for depression
5. Stress hormone, depression trigger obesity in girls
6. Psychiatrys main method to prevent mistaken diagnoses of depression doesnt work: NYU study
7. Brain Balancing Gives Hope for Sufferers of Depression, Stress, and Insomnia at New Life Brain Center
8. Video games may help combat depression in older adults
9. Obesity and Depression: A Vicious Circle?
10. Major depression more than doubles risk of dementia among adults with diabetes
11. Study shows phyical therapy exercise program can reduce risk of postnatal depression in new mothers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... NexTec Group ... a group of 100 organizations honored for their accomplishments in the field of midmarket ... growth, industry leadership and recognition, and innovation. Selection is not based on revenue and ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow ... ease," said Christina Austin - CEO of Pixel Film Studios. , On Tour’s ... the style and animation of their slideshows. Place each slide on top of another ...
(Date:1/14/2017)... ... January 14, 2017 , ... Healthy living brand Moody Zook ... charcoal products. With more and more people opting to go organic in their ... they cater to specific needs. , Moody Zook focused particularly on their newly ...
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in Lung Cancer ... 2017. This Congress is expertly designed to meet the educational needs of European ... cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at the University ...
(Date:1/13/2017)... ... January 13, 2017 , ... An inventor from Virginia Beach, Va., is ... in order to diversify my outfits, so he decided to design something that enhances ... enhances the appearance of a belt to allow for quick, easy changing of its ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... January 13, 2017 This morning, ... how they have fared at yesterday,s closing bell: Clovis ... Inc. (NASDAQ: GALE ), and ACADIA Pharmaceuticals ... cellular and biomolecular processes to develop technologies and products ... footprint, feed the hungry, use less and cleaner energy, ...
(Date:1/13/2017)... , Jan. 13, 2017  Secretary of Health ... professors, and community members at Misericordia University and discussed ... in Pennsylvania . "The ... seen so far in my professional career," Secretary Murphy ... has been hit hard by heroin and prescription opioid ...
(Date:1/13/2017)... -- Research and Markets has announced the addition of ... to their offering. ... Cystic fibrosis (CF) is a progressive genetic condition and is ... conductance regulator (CFTR) gene from both parents. The defective CFTR genes ... in the buildup of a thick and sticky mucus in the ...
Breaking Medicine Technology: